T. Rowe Price Associates
ALDX icon

T. Rowe Price Associates’s Aldeyra Therapeutics ALDX Stock Holding History

T. Rowe Price Associates’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75K Sell
35,091
-38,681
-52% -$66.5K ﹤0.01% 3174
2026
Q1 		$125K Buy
73,772
+9,510
+15% +$41.7K ﹤0.01% 2947
2025
Q4 		$333K Hold
64,262
– – ﹤0.01% 2596
2025
Q3 		$336K Buy
64,262
+15,579
+32% +$81.2K ﹤0.01% 2550
2025
Q2 		$187K Buy
48,683
+13,600
+39% +$35.2K ﹤0.01% 2736
2025
Q1 		$202K Buy
35,083
+2,978
+9% +$17.6K ﹤0.01% 2633
2024
Q4 		$161K Sell
32,105
-23,517
-42% -$121K ﹤0.01% 2752
2024
Q3 		$300K Buy
55,622
+7,149
+15% +$34K ﹤0.01% 2477
2024
Q2 		$161K Buy
48,473
+200
+0.4% +$783 ﹤0.01% 2642
2024
Q1 		$158K Buy
48,273
+3,446
+8% +$11.3K ﹤0.01% 2687
2023
Q4 		$158K Buy
44,827
+4,935
+12% +$15.2K ﹤0.01% 2610
2023
Q3 		$267K Buy
39,892
+742
+2% +$5.5K ﹤0.01% 2384
2023
Q2 		$329K Sell
39,150
-10,437
-21% -$103K ﹤0.01% 2323
2023
Q1 		$493K Hold
49,587
– – ﹤0.01% 2113
2022
Q4 		$345K Buy
49,587
+15,200
+44% +$86.9K ﹤0.01% 2321
2022
Q3 		$184K Sell
34,387
-10,923
-24% -$65.5K ﹤0.01% 2576
2022
Q2 		$181K Sell
45,310
-1,054
-2% -$3.63K ﹤0.01% 2630
2022
Q1 		$206K Buy
46,364
+9,300
+25% +$37K ﹤0.01% 2701
2021
Q4 		$148K Buy
37,064
+25,900
+232% +$198K ﹤0.01% 2814
2021
Q3 		$98K Sell
11,164
-100
-0.9% -$918 ﹤0.01% 2849
2021
Q2 		$128K Buy
+11,264
New +$135K ﹤0.01% 2811

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

T. Rowe Price Associates's ALDX Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Aldeyra Therapeutics (ALDX) stake by 52% in Q2 2026, selling an estimated $66.5K and leaving 35,091 shares worth $75K. The position accounts for ﹤0.01% of the portfolio, ranked #3174.

T. Rowe Price Associates first reported a position in ALDX in Q2 2021 and has held it in 21 quarters since. The position peaked at $493K in Q1 2023. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • T. Rowe Price Associates held 35,091 shares of Aldeyra Therapeutics worth $75K as of Q2 2026.
  • T. Rowe Price Associates sold 38,681 Aldeyra Therapeutics shares in Q2 2026, an estimated $66.5K.
  • Aldeyra Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3174 holding.
  • T. Rowe Price Associates first reported a position in Aldeyra Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Aldeyra Therapeutics position peaked at $493K in Q1 2023.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.